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In most situations the use of Rh Immune Globulin 
(RhIG) for the prevention of Rh sub(o)(D) immunization in 
Rh-negative women of child-bearing age is routine. The 
following nine unusual situations are based on 
telephone calls received by Technical Services of Ortho 
Diagnostic Systems. Comments are not meant to he 
all-inclusive and the author suggests consultation when 
in doubt about a particular case. 
Case One 
Situation: An Rh-negative woman is bleeding at 35 
weeks gestation. Until now her pregnancy has been 
uneventful. She was given Rh Immune Globulin (RhIG) 
at 28 weeks gestation. Should she receive an additional 
dose now because of the bleeding? 
Comments: Yes, the fact that the mother is 
experiencing vaginal bleeding does not necessarily 
mean that there is also a fetal-maternal hemorrhage 
(FMH); however, one should assume that an FMH may 
be concomitant. 
The half-life of gamma globulins is 21-23 days. 
Therefore, in this case, at least two “half-lives” have 
expired since the 28-week injection. This amount of 
time has reduced the RhIG to about 75 µg, which is 
sufficient to suppress the response of only three or 
four mL of red cells. Screening tests for FMH are not 
designed to detect small quantities of fetal cells. For 
example, the package insert of one of the commercially 
available screening kits states “Demonstration of 
volumes of fetal red cells less than 7.5 mL but greater 
than 2.5 mL will depend on the care taken in 
performing the test.”’ Because three or four mL of 
fetal cells might not be detected by a FMH screening 
test, a fail-safe approach should he taken with a 
negative test and it is recommended that one vial of 
RhIG should be given. 
If a screening test for FMH is positive, the amount 
of the bleed should be determined hy doing a ’  
Kleihauer-Betke (K-B) sup(2) or enzyme-linked antiglobulin 
test (ELAT), sup(3) and, depending on the results, the 
appropriate number of vials of RhIG should be given. 
It is best to ignore the residual RhIG from the 28-week 
injection in calculating the current needs. 
Case Two 
Situation: RhIG was given to an Rh-negative woman 
at 28 weeks gestation. The patient is now three weeks 
past the expected date of delivery. Should RhIG be 
given now? 
Comments: Yes, another injection of RhIG should be 
given if 12 weeks have elapsed since the last injection. 
Based on the half-life of gamma globulins (21-23 days), 
the amount of RhIG present at the end of 12 weeks 
will be insufficient to suppress immunization from 
even a small amount of blood. Bowman has stated 
“. , , we don’t let a woman go more than seven days 
past the 12 weeks before calling her in and giving her 
the second injection.”* 
Case Three 
Situation: An Rh-negative woman was delivered of a 
healthy Rh-positive baby. The test for FMH was 
negative, and a single dose of RhIG was given. The 
woman was in the hospital for 5 days because of 
postpartum complications. On the fourth day after 
delivery, the obstetrician ordered an antibody screen- 
ing test. The reason for the order was to “evaluate the 
effectiveness of the RhIG.” 
Comments: There is no scientific evidence to support 
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the contention that the absence of circulating antibody 
indicates an inadequate dose of RhIG, as the exact 
action of RhIG in suppressing the immune response 
is not known. There are no data to support specula- 
tion that antigen sites are blocked by antibody, leav- 
ing red cells immunologically inert and that all sites 
may not have been blocked unless excess antibody is 
detected. The site of action is probably at a more basic 
immunologic level. Many studies have shown that the 
recommended dose suppresses antibody production 
and it is meaningless to look for antibody in the 
serum. sup(5) 
Case Four 
Sitnation: A patient received eight units of Rh-positive 
blood in the emergency room. The patient was later 
found to be Rh-negative and the physician came to the 
blood bank to determine the best course of action. 
Comments: Based on the following facts, it would re- 
quire 128 vials of RhIG to suppress the immune 
response to eight units of blood: 
480 mL whole blood per unit 
1 vial RhIG suppresses 30 mL whole blood 
each unit of blood requires 16 vials of RhIG 
8 units of blood = 128 vials of RhlG. 
Before going to such measures, one question is 
important. Is the patient male or female and, iffemale, 
what is her reproductive potential? The package in- 
sert for RhoGAM* Rh sub(o)(D) Immune Globulin (Human) 
states “RhIG may be administered intramuscularly to 
prevent isoimmunization in eligible Rh-negative 
premenopausal females who receive Rh-positive red 
cells by transfusion, whether inadvertently or in 
association with leukocyte or platelet therapy.” In other 
words, one should carefully weigh the consequences 
of immunization against the cost and trauma of ad- 
ministering massive intramuscular doses of RhIG to 
prevent immunization of any patient except females 
who may still bear children. 
Case Five 
Situation: An Rh-negative woman has had two 
previous pregnancies and received antepartum and 
postpartum RhIG with both pregnancies. She is preg- 
nant again, and her initial antibody screening test is 
positive; the antibody has been identified as 
anti-Rh sub(o)(D). 
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Comments: There are several possible scenarios that 
could account for this immunization. First, the woman 
could have had an unprotected (spontaneous or 
therapeutic) abortion since the last fullterm pregnancy. 
Second, there might have been an undetected excessive 
FMH at the termination of the last pregnancy. Third, 
there might have been a FMH prior to the 28-week 
antepartum injection of RhIG. Statistics show that 
about 0.14 percent of women who have been proper- 
ly treated during past pregnancies still become 
immunized prior to 29 weeks gestation. sup(6) The most 
likely cause is transplacental passage of fetal cells dur- 
ing pregnancy prior to the 28-week injection of RhIG. 
In addition, a prior unrecognized or concealed 
pregnancy cannot be discounted. 
Case Six 
Situation: An Rh-negative woman had amniocentesis 
done at 15 weeks gestation to determine the possibility 
of an inherited defect. Should a full dose (300 µg) of 
RhIG be given? 
Comments: Yes, a full dose of RhIG (300 µg) should 
be administered in any pregnancy that is expected to 
continue, regardless of the time of the amniocentesis. 
The micro dose of RhIG (50 µg) should be used only 
at the termination of pregnancy up to and including 
12 weeks gestation. 
If RhIG is given at 15-16 weeks gestation, a regular 
antepartum dose at 27-28 weeks must be given, 
because no more than 12 weeks should elapse between 
doses. The 12-week rule is based on both the half-life 
of RhIG and the concept of augmentation. There are 
limited studies that suggest there may be an enhance- 
ment of the immune response in the presence of a 
small amount of antibody, which is the opposite of 
the conditions required for suppression. sup(7) Twelve 
weeks after a 300-µg dose of RhIG, the amount of 
immune globulin will have been reduced to less than 
20 µg. Augmentation of the immune response is 
thought to be possible when fetal cells enter the cir- 
culation at the time when only a few micrograms of 
RhIG remain. These conditions could exist if more 
than 12 weeks elapse before another injection is given. 
Case Seven 
Situation: An Rh-negative woman is pregnant with 
twins, and amniocentesis was done at 16 weeks for 
genetic purposes. The twins are dizygotic and have 
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separate amnionic sacks; therefore, amniocentesis was 
performed at two separate sites. Should two vials of 
RhIG be given? 
Comments: One vial of RhIG (300 µg) is recommended 
following any amniocentesis. If there is any reason to 
believe that difficulty was encountered (eg, a bloody 
tap), a FMH screening test can be performed to deter- 
mine if there was sufficient bleeding to warrant doing 
a quantitative test. 
Case Eight 
Situation: Following a normal delivery, the rosette 
screening test for FMH was strongly positive while the 
K-B test was negative. 
Comments: First, both tests should be repeated. sup(2) 
Unless the K-B test is done frequently and by ex- 
perienced technologists, it would be best to ask for 
consultation from a reference laboratory. The K-B test 
detects cells containing fetal hemoglobin, regardless 
of whether the cells are of fetal or maternal origin. 
On the other hand, a rosetting test determines the 
presence of D-positive cells (presumably fetal cells) in 
a majority of D-negative (maternal) cells. sup(2) The above 
case description is typical if the mother is, in fact, 
D-positive or D sup(u) rather than D-negative. 
Case Nine 
Situation: An Rh-negative woman was delivered at 
home 5 days ago and has just now called the doctor 
to inquire about receiving RhIG. Should it be given 
at this late date? 
Comments: Postpartum prophylaxis should be 
administered as soon as possible, preferably within 7 2  
hours of delivery. The time of 72 hours was selected 
rather arbitrarily when the clinical trials were done 
to establish the efficacy of RhoGAM. It was assumed 
to be sufficient time for treatment to be given even 
in unusual circumstances. For this reason, there are 
no data to validate how much longer than 72 hours 
the injection will be effective, but it is unreasonable 
to believe that it would be effective at 7 2  hours and 
suddenly no longer effective at 7 5  or 80 hours. RhIG 
should be given after 7 2  hours; however, it should be 
recognized that the longer the time period, the less 
likely immunosuppression will be achieved. 
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